Breakingviews TV: Going Loxo

Eli Lilly is paying a huge premium for the cancer-treating upstart and might not get a return for years. But Antony Currie and Robert Cyran explain that Loxo’s appeal lies in how it looks for what causes cancer, not where it occurs. That could be a big money-spinner.

from Reuters Video: Breakingviews https://reut.rs/2RbU76m